• Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • NP and PA
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
  • Vitiligo
  • Wound Care

Poll

POLL: Which September FDA Approval Were You Most Excited About?

Click here to answer this week's poll.

Which September FDA Approval Were You Most Excited About?

Dupilumab for prurigo nodularis
Deucravacitinib for psoriasis
DaxibotulinumtoxinA for glabellar lines
Spesolimab for generalized pustular psoriasis

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

© 2025 MJH Life Sciences

All rights reserved.